Dr Reddy’s Laboratories has announced the launch of the prescription drug Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss (FPHL). The launch follows the first-ever approval of the additional indication by the Central Drugs Standard Control Organization (COSCO) in India for the use of Minoxidil topical solution USP 2% and 5% for treatment of FPHL. As a first-line treatment option, Minoxidil topical solution will become available for FPHL in India. While Minoxidil topical solution has been approved for the treatment of alopecia in men (male pattern baldness), there are presently no other drugs approved for the treatment of FPHL in India. The most common cause of hair loss in women is female pattern hair loss and its prevalence increases with advancing age, often leading to psychological distress. FPHL prevalence may also increase post menopause with a possible hormonal influence. Minoxidil Topical Solution acts like a peripheral vasodilator that further enhances microcirculation to hair follicles. It can reverse the hair loss process of androgenetic alopecia by increasing the diameter of the hair shaft. It will be available only if prescribed by a dermatologist. This approval has marked the first-ever given to a first-line treatment option for female pattern hair loss, and it truly fulfils a hitherto unmet need.